WO2008049657A3 - Verwendung von (meth)acrylat-copolymeren in retard-arzneiformen zur verringerung des einflusses von ethanol auf die wirkstofffreisetzung - Google Patents

Verwendung von (meth)acrylat-copolymeren in retard-arzneiformen zur verringerung des einflusses von ethanol auf die wirkstofffreisetzung Download PDF

Info

Publication number
WO2008049657A3
WO2008049657A3 PCT/EP2007/058100 EP2007058100W WO2008049657A3 WO 2008049657 A3 WO2008049657 A3 WO 2008049657A3 EP 2007058100 W EP2007058100 W EP 2007058100W WO 2008049657 A3 WO2008049657 A3 WO 2008049657A3
Authority
WO
WIPO (PCT)
Prior art keywords
release
active ingredient
meth
influence
acrylate copolymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/058100
Other languages
English (en)
French (fr)
Other versions
WO2008049657A2 (de
Inventor
Hans-Ulrich Petereit
Brigitte Skalsky
Diego Gallardo
Manfred Assmus
Andreas Gryczke
Wolfgang Weisbrod
Felix Hofmann
Hans Baer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roehm GmbH Darmstadt
Original Assignee
Evonik Roehm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm GmbH filed Critical Evonik Roehm GmbH
Publication of WO2008049657A2 publication Critical patent/WO2008049657A2/de
Publication of WO2008049657A3 publication Critical patent/WO2008049657A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

Die Erfindung betrifft die Verwendung von magensaftunlöslichen (Meth)acrylat- Copolymeren in oralen Retard-Arzneiformen als Matrixbildner für den enthaltenen Wirkstoff zur Veringerung des Effektes der Beschleunigung oder Verlangsamung der Wirkstofffreisetzung durch den Einfluss von Ethanol unter in-vitro Bedingungen.
PCT/EP2007/058100 2006-10-26 2007-08-06 Verwendung von (meth)acrylat-copolymeren in retard-arzneiformen zur verringerung des einflusses von ethanol auf die wirkstofffreisetzung Ceased WO2008049657A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006051020.8 2006-10-26
DE200610051020 DE102006051020A1 (de) 2006-10-26 2006-10-26 Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung

Publications (2)

Publication Number Publication Date
WO2008049657A2 WO2008049657A2 (de) 2008-05-02
WO2008049657A3 true WO2008049657A3 (de) 2008-10-30

Family

ID=38521102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/058100 Ceased WO2008049657A2 (de) 2006-10-26 2007-08-06 Verwendung von (meth)acrylat-copolymeren in retard-arzneiformen zur verringerung des einflusses von ethanol auf die wirkstofffreisetzung

Country Status (3)

Country Link
DE (1) DE102006051020A1 (de)
TW (1) TW200833372A (de)
WO (1) WO2008049657A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2923102C (en) 2007-08-13 2019-10-15 Omeho Life Sciences Inc. Abuse resistant drugs, method of use and method of making
CN104984343B (zh) * 2008-09-24 2019-04-02 赢创罗姆有限公司 耐受乙醇影响的非阿片类药物的pH依赖性受控释放的药物组合物
US9757343B2 (en) * 2008-09-24 2017-09-12 Evonik Röhm Gmbh PH-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
JP5453434B2 (ja) 2008-09-24 2014-03-26 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング エタノールの影響に対する耐性を有するオピオイドではないｐＨ依存の制御放出の医薬組成物
CN105287434A (zh) * 2009-03-18 2016-02-03 赢创罗姆有限公司 采用含有中性乙烯基聚合物和赋形剂的包衣的具有耐乙醇影响的控释药物组合物
US9730899B2 (en) * 2009-03-18 2017-08-15 Evonik Roehm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
WO2010105673A1 (en) * 2009-03-18 2010-09-23 Evonik Röhm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
NZ603173A (en) 2010-05-10 2014-10-31 Euro Celtique Sa Manufacturing of active-free granules and tablets comprising the same
WO2011141490A1 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Combination of active loaded granules with additional actives
KR20130030260A (ko) 2010-05-10 2013-03-26 유로-셀티큐 에스.에이. 히드로모르폰 및 날록손을 포함하는 제약 조성물
MX353427B (es) 2011-06-17 2018-01-12 Evonik Roehm Gmbh Composicion de recubrimiento adecuada para formas de dosis farmaceuticas o nutraceuticas.
JP5832645B2 (ja) 2011-06-17 2015-12-16 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツングＥｖｏｎｉｋ Ｒｏｅｈｍ ＧｍｂＨ 医薬剤形又は栄養補助剤形に適したコーティング組成物
CN103501768B (zh) 2011-06-17 2016-11-09 赢创罗姆有限公司 具有抗乙醇影响抗性的抗胃酸的药物或营养组合物
WO2014146093A2 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
EP3068397A1 (de) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphon und naloxon zur behandlung von schmerzen und opioid-reizdarm-dysfunktionssyndrom
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
BR112021017735A2 (pt) 2019-03-11 2021-11-16 Evonik Operations Gmbh Forma de dosagem que compreende uma matriz polimérica

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074033A1 (en) * 2002-02-11 2003-09-12 Pliva-Istrazivacki Institut D.O.O. Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
WO2006079550A2 (en) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
WO2006094083A1 (en) * 2005-02-28 2006-09-08 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
WO2007053698A2 (en) * 2005-10-31 2007-05-10 Alza Corporation Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
WO2007085024A2 (en) * 2006-01-21 2007-07-26 Abbott Gmbh & Co. Kg Dosage form and method for the delivery of drugs of abuse
WO2008011595A2 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152414A (en) * 1978-08-18 1979-05-01 Iowa State University Research Foundation, Inc. Combination vaccine for swine dysentery and method of use
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US20020106412A1 (en) * 2000-07-10 2002-08-08 Therics, Inc Method and materials for controlling migration of binder liquid in a powder
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
DE10058771A1 (de) * 2000-11-27 2002-06-06 Falk Pharma Gmbh Coazervierungsverfahren zur Herstellung von verzögert feisetzenden Arzneimitteln
JP5259183B2 (ja) * 2004-07-01 2013-08-07 グリューネンタール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 乱用に対して保護された経口剤形

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074033A1 (en) * 2002-02-11 2003-09-12 Pliva-Istrazivacki Institut D.O.O. Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
WO2006079550A2 (en) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
WO2006094083A1 (en) * 2005-02-28 2006-09-08 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
WO2007053698A2 (en) * 2005-10-31 2007-05-10 Alza Corporation Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
WO2007085024A2 (en) * 2006-01-21 2007-07-26 Abbott Gmbh & Co. Kg Dosage form and method for the delivery of drugs of abuse
WO2008011595A2 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system

Also Published As

Publication number Publication date
WO2008049657A2 (de) 2008-05-02
DE102006051020A1 (de) 2008-04-30
TW200833372A (en) 2008-08-16

Similar Documents

Publication Publication Date Title
TW200833372A (en) Use of (meth)acrylate copolymers in delayed-release pharmaceutical forms for decreasing the influence of ethanol on the release of active compound
WO2010066749A3 (en) Ulipristal acetate tablets
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2006084164A3 (en) Gastric retention and controlled release delivery system
WO2009063222A3 (en) Solid compositions
PL1906939T3 (pl) Zastosowanie częściowo zobojętnianego, anionowego kopolimeru (met)akrylanowego jako powłoki do wytwarzania postaci leku z uwalnianiem substancji czynnej przy obniżonych wartościach pH
WO2009117130A3 (en) Extended release forumulation containing a wax
EP3272337A3 (de) Tabletten
WO2008052033A3 (en) Ibuprofen composition
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
WO2009051022A3 (en) Matrix-type pharmaceutical solid preparation
WO2011101866A3 (en) Gastric retention formulation containing baclofen
WO2011053003A3 (en) Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2009068708A3 (es) Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo
WO2008113901A3 (fr) Composition à libération prolongée de lévétiracetam et procédé de préparation.
WO2008005353A3 (en) Immediate-release tablet formulations of a thrombin receptor antagonist
WO2007016284A3 (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily
WO2007099555A3 (en) Pharmaceutical tablet compositions containing irbesartan
WO2008060546A3 (en) Oral formulations
WO2007110765A3 (en) Processes for the preparation of octreotide
WO2011064797A3 (en) Controlled release pharmaceutical compositions of galantamine
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
WO2009060064A3 (en) Pharmaceutical formulations for the oral administration of ppi

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07802495

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07802495

Country of ref document: EP

Kind code of ref document: A2